Application submitted for EU approval of teclistamab monotherapy at first relapse
A Type II variation application has been submitted to the European Medicines Agency seeking approval of teclistamab for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy, according to a press release. The application is supported by topline data from the phase 3 MajesTEC-9 study, which showed improved progression-free survival and overall survival over standard-of-care in patients with RRMM who have received 1–3 prior lines of therapy, including an anti-CD38 monoclonal antibody and lenalidomide.

Intensified triplet-based maintenance post-transplant improves outcomes
Lenalidomide maintenance after autologous stem cell transplant is the current standard of care in newly diagnosed multiple myeloma (NDMM). Findings from the phase 3 ATLAS trial, reported in The Lancet Haematology, show that maintenance with carfilzomib-lenalidomide-dexamethasone (KRd) improved four-year progression-free survival (PFS), compared with single-agent lenalidomide maintenance. Notably, the study tested the intensified maintenance approach in the context of minimal residual disease (MRD)-based de-escalation and individualized risk assessment.

ASCO updates guidelines on effective communication for oncology clinicians
The American Society of Clinical Oncology published updated guidelines on effective patient communication for oncology clinicians in the Journal of Clinical Oncology. The 2026 version expands upon the first iteration of the Patient-Clinician Communication guidelines, published in 2017, covering the additional topics of communication in the context of telehealth and interprofessional teams, and establishing boundaries.

Review summarizes evidence and positions selinexor-based myeloma therapy
In a review published in ESMO Open, myeloma experts from Italy provide an overview of selinexor in multiple myeloma (MM), including its mechanism of action and the latest clinical evidence for selinexor-based regimens, and offer practical insights on the positioning of selinexor-based therapy in the evolving MM treatment landscape.

Tumor debulking with chemotherapy can improve response to teclistamab
A subset of patients with RRMM do not respond to bispecific antibody (bsAb) therapy. According to a report in Blood Cancer Discovery, debulking chemotherapy helped restore the response to teclistamab, a BCMA-targeted bsAb, in patients with RRMM who had primary resistance to teclistamab.

Excess BMI is a leading risk factor for progression from MGUS to MM
In a multivariable-adjusted population attributable fractions analysis of a cohort of over 35,000 US Veterans with monoclonal gammopathy of undetermined significance (MGUS), excess body mass index (≥25 kg/m²) was the leading risk factor for progression from MGUS to MM. These findings, reported in the International Journal of Cancer, underscore the importance of weight management as a modifiable risk factor in this population impacted by myeloma.